363 related articles for article (PubMed ID: 33918323)
1. The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment-A Narrative Review.
Kryszkowski W; Boczek T
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33918323
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
Chavez-Noriega LE; Schaffhauser H; Campbell UC
Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
[TBL] [Abstract][Full Text] [Related]
3. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
[TBL] [Abstract][Full Text] [Related]
4. The possible involvement of metabotropic glutamate receptors in schizophrenia.
Krivoy A; Fischel T; Weizman A
Eur Neuropsychopharmacol; 2008 Jun; 18(6):395-405. PubMed ID: 18063347
[TBL] [Abstract][Full Text] [Related]
5. Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.
Rubio MD; Drummond JB; Meador-Woodruff JH
Biomol Ther (Seoul); 2012 Jan; 20(1):1-18. PubMed ID: 24116269
[TBL] [Abstract][Full Text] [Related]
6. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
[TBL] [Abstract][Full Text] [Related]
7. Ionotropic glutamate receptors as therapeutic targets in schizophrenia.
Coyle JT; Tsai G; Goff DC
Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):183-9. PubMed ID: 12769626
[TBL] [Abstract][Full Text] [Related]
8. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia.
Meador-Woodruff JH; Clinton SM; Beneyto M; McCullumsmith RE
Ann N Y Acad Sci; 2003 Nov; 1003():75-93. PubMed ID: 14684436
[TBL] [Abstract][Full Text] [Related]
9. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
Iwata Y; Nakajima S; Suzuki T; Keefe RS; Plitman E; Chung JK; Caravaggio F; Mimura M; Graff-Guerrero A; Uchida H
Mol Psychiatry; 2015 Oct; 20(10):1151-60. PubMed ID: 26077694
[TBL] [Abstract][Full Text] [Related]
10. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
Kanuma K; Aoki T; Shimazaki Y
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
Heresco-Levy U
Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
[TBL] [Abstract][Full Text] [Related]
13. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
14. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy.
Alexander GM; Godwin DW
Epilepsy Res; 2006 Sep; 71(1):1-22. PubMed ID: 16787741
[TBL] [Abstract][Full Text] [Related]
15. [Glutamatergic neurotransmission in schizophrenics].
Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
[TBL] [Abstract][Full Text] [Related]
16. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia.
Moghaddam B
Psychopharmacology (Berl); 2004 Jun; 174(1):39-44. PubMed ID: 15205877
[TBL] [Abstract][Full Text] [Related]
17. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
[TBL] [Abstract][Full Text] [Related]
18. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
de Bartolomeis A; Fiore G; Iasevoli F
Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
[TBL] [Abstract][Full Text] [Related]
19. Ionotropic and metabotropic glutamate receptor structure and pharmacology.
Kew JN; Kemp JA
Psychopharmacology (Berl); 2005 Apr; 179(1):4-29. PubMed ID: 15731895
[TBL] [Abstract][Full Text] [Related]
20. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
Chaki S; Hikichi H
Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
